08.05.2013 - Belgian single chain camelidae antibody producer Ablynx has started development of an anti-IgE nanobody, code-named ALV-0962.
The Ghent-based company announced the compound will enter clinical development after Q2/2014. Ablynx believes its treatment of severe allergic asthma can outcompete Roche’s /Novartis’ marketed allergic asthma antibody Xolair (omalizumab) due to its "unique" dual mode of action. The company suggested the preclinical compound could displace receptor-bound IgE as well as binding free IgE molecules.
Due to its mode of action, Ablynx believes that ALX-0962 could address a wider patient population, including those currently not eligible to be treated with omalizumab (Xolair®). Currently, many allergic asthma treatments are in clinical development including Phase II compounds from Swedish Resistentia Pharmaceuticals AB, Takeda, Actelion or Cytos Biotechnology (CYT003-QbG10).
IgE is a key mediator in initiating an allergic reaction upon allergen exposure. IgE is a clinically and commercially validated mechanism to treat allergic asthma. Omalizumab currently is the only anti-IgE biologic approved for the treatment of patients with moderate to severe persistent allergic asthma, inadequately controlled with inhaled corticosteroids. Xolair® generated sales of $1.26bn in 2012.
15.09.2014 Jean Claude Juncker, the European Commission President-elect revealed his new Commissioners last week, whilst announcing a change in the units dealing with medicines, medical devices and health technology.
12.09.2014 The 2011 collaboration of Boehringer Ingelheim and Eli Lilly is bearing fruit. An insulin biosimilar developed through the partnership has now been approved in Europe - the first-ever generic version of this class.
09.09.2014 In the midst of the hustle and bustle of the European Respiratory Society’s International Congress 2014, Astrazeneca quietly announced the disappointing results of its latest benralizumab study.
29.08.2014 Just a week ago, Glaxosmithkline defused the WHO’s claim that an Ebola vaccine could be ready by 2015. Now, the British company’s own candidate vaccine is to be rushed to human trials with the help of funding from an international consortium.